Colin John Meyer, Chief Research Officer at REATA PHARMACEUTICALS INC (RETA), sold 114,875 shares at $143.54 ($16.4M) on 2021-06-14, disclosed to the SEC on 2021-06-16.
Open-market sale of $16.4M RETA by Chief Research Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $143.54 | 12,615 | $1.8M | 11.1% |
| 2 | $143.54 | 12,615 | $1.8M | 11.1% |
| 3 | $144.44 | 4,225 | $610K | 3.7% |
| 4 | $145.49 | 2,760 | $402K | 2.5% |
| 5 | $145.49 | 2,760 | $402K | 2.5% |
| 6 | $146.15 | 400 |
| $58K |
| 0.4% |
| 7 | $139.14 | 3,814 | $531K | 3.2% |
| 8 | $139.14 | 3,814 | $531K | 3.2% |
| 9 | $139.98 | 4,107 | $575K | 3.5% |
| 10 | $139.98 | 4,107 | $575K | 3.5% |
| 11 | $141.09 | 6,494 | $916K | 5.6% |
| 12 | $141.09 | 6,494 | $916K | 5.6% |
| 13 | $142.08 | 12,518 | $1.8M | 10.9% |
| 14 | $142.08 | 12,518 | $1.8M | 10.9% |
| 15 | $142.83 | 8,867 | $1.3M | 7.7% |
| 16 | $142.83 | 8,867 | $1.3M | 7.7% |
| 17 | $143.98 | 2,483 | $358K | 2.2% |
| 18 | $143.98 | 2,483 | $358K | 2.2% |
| 19 | $145.11 | 1,217 | $177K | 1.1% |
| 20 | $145.11 | 1,217 | $177K | 1.1% |
| 21 | $145.92 | 500 | $73K | 0.4% |
| Total | $142.49 avg | 114,875 | $16.4M | 100% |
| Filing → |
| RETA | SELL | 2023-03-08 | $105K | — | Filing → |
| RETA | SELL | 2023-03-06 | $16.3M | — | Filing → |
| RETA | SELL | 2020-11-18 | $8.0M | — | Filing → |